Trial
NCT04835714
A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Boehringer Ingelheim
Collaborators
—
Condition
Solid Tumors, KRAS Mutation
Intervention
BI 1701963
Why stopped
Sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-01